 NEW YORK and PLANEGG, Germany, June 02, 2021 GLOBE NEWSWIRE -- Royalty Pharma plc Nasdaq: RPRX and MorphoSys AG FSE: MOR; Nasdaq: MOR today announced a 2.025 billion strategic funding partnership as part of MorphoSys 1.7 billion acquisition of Constellation Pharmaceuticals Nasdaq: CNST. This partnership is expected to fuel the expansion of the combined companys capabilities to help enable the development and potential approvals of important cancer treatments. 